Fig. 2
From: A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic
Flow cytometry analysis a VEGFR2 expression analysis on the surface of 293KDR and HEK-293 cells using commercially available anti-VEGFR2 PE-conjugated antibody: Blue and green graphs: Unstained and stained HEK-293 cells, respectively; Orange and red graphs: Unstained and stained 293KDR cells, respectively. b Binding potency analysis of VGRmIL2-IC and 3VGR19 Nb towards 293KDR cells using a homemade rabbit anti-camel antibody followed by FITC-conjugated anti-rabbit IgG antibody, gray graph: Untreated control cells; Red graph: Secondary antibody alone control; Light blue graph: LivIL2-IC as a non-specific Nb-IL2 control; Dark blue and green graphs: 3VGR19 Nb and VGRmIL2-IC treated cells, respectively